174 related articles for article (PubMed ID: 12449033)
1. [Clinical pharmacology of nucleoside analogues].
Milano G; Chamorey AL; Thyss A
Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
3. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
4. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
5. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
[TBL] [Abstract][Full Text] [Related]
7. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
Santini V; D'Ippolito G; Bernabei PA; Zoccolante A; Ermini A; Rossi-Ferrini P
Leuk Res; 1996 Jan; 20(1):37-45. PubMed ID: 8632676
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Hubeek I; Peters GJ; Broekhuizen AJ; Kaspers GJ
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1513-6. PubMed ID: 15571288
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
Kemena A; Gandhi V; Shewach DS; Keating M; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(3):193-9. PubMed ID: 1464155
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Heinemann V; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
[TBL] [Abstract][Full Text] [Related]
13. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine.
Neff T; Blau CA
Exp Hematol; 1996 Sep; 24(11):1340-6. PubMed ID: 8862446
[TBL] [Abstract][Full Text] [Related]
14. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Gandhi V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Amsailale R; Van Den Neste E; Arts A; Starczewska E; Bontemps F; Smal C
Biochem Pharmacol; 2012 Jul; 84(1):43-51. PubMed ID: 22490700
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Eliopoulos N; Cournoyer D; Momparler RL
Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951
[TBL] [Abstract][Full Text] [Related]
19. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett W; Huang P; Searcy CE; Gandhi V
Semin Oncol; 1996 Oct; 23(5 Suppl 10):3-15. PubMed ID: 8893876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
